Figure 1 | Scientific Reports

Figure 1

From: Patients with III and IV category of the Bethesda System under levothyroxine non-suppressive therapy have a lower rate of thyroid malignancy

Figure 1

Selection of study group from 4,716 individuals referred for surgery from 2008 to 2017. All participants underwent UG-FNAB before surgery. Histopathological verification was obtained for all participants. UG-FNAB: ultrasound guided fine needle aspiration biopsy, AUS/FLUS: atypia of undetermined significance or follicular lesion of undetermined significance, FN/SFN: follicular neoplasm or suspicious for follicular neoplasm, TNs: thyroid nodules, MEN: multiple endocrine neoplasm, TSH: thyroid stimulating hormone.

Back to article page